|
table 1
Neurovisual Impairment: A Frequent Complication of
Alpha-Interferon Treatment in Chronic Viral Hepatitis
|
table 1. Clinical and
Laboratory Characteristics of Patients Studied
|
|
| Parameter |
Patients (n = 53) |
|
| Sex (% males) |
27 (50.9%) |
| Age (yrs)* |
52.5 ± 14.4 (55, 16-74) |
| Type of viral hepatitis |
| HBV-positive (n, %) |
22 (41.5%) |
| HCV-positive (n, %) |
31 (58.5%) |
| Presence of cirrhosis (n, %) |
24 (45.3%) |
Child-Pugh score |
5 (5-12) |
| Baseline diabetes (n, %) |
4 (7.5%).gif) |
| Baseline hypertension (n, %) |
13 (24.5%) |
Baseline serum cholesterol .gif) 240 mg% (n, %) |
3 (5.7%) |
| Baseline total cholesterol/HDL ratio >5 (n,
%) |
9 (17.0%) |
| Baseline AST (IU/ml)* |
95 ± 88 (74.5, 17-555) |
| Interferon-a2b dose per injection (MU)*,§ |
3.2 ± 0.7 (3, 1.2-5) |
| Cumulative interferon dose (MU)*,# |
386 ± 150 (392, 96-762) |
| Total interferon treatment time (months)*,# |
10.2 ± 3.4 (11, 1.8-18.3) |
|
*
Mean ± SD, (median, range).
Median (range).
Four additional patients (7.5%)
had positive oral glucose tolerance test.
§ Administered thrice
weekly.
#Up to the second ophthalmological evaluation. |
|
Return To Article
|
